AZD1222 claims 79% effecacy in pivotal US... Following assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US. more ➔
EMA recommends to continue AZD1222 vaccina...On Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine. more ➔
Novel COVID antibody enters clinical testi...German CORAT Therapeutics GmbH got the greenlight for Phase Ib/II testing of COR-101, an antibody that reduced virus load in the lung by more than 99 % within three days. more ➔
Don’t bet only on vaccines!First emergency approvals of vaccines and antibody drugs in less than a year are great achievements of modern biotechnology in our battle against the COVID-19 pandemic, but we still have no efficient … more ➔
B.1.1.7 variant associated with higher mor...The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests. more ➔
Roche in take-over deal with GenMark Diagn...Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample. more ➔
Media hype on Denmarks decision to halt...While media reports suggest AstraZenecas COVID-19 jab might have caused blot clots, the EMA didn’t confirm a causal relationship. more ➔
Roche Phase III study misses COVID-19 endp...Swiss Roche AG has missed the primary endpoint in the REMDACTA trial in patients with severe COVID-19 pneumonia. more ➔
BioPhero A/S raises US$17m in Series A fun...Danish sustainable crop protection company, BioPhero AS, has raised $17m in Series A funding led by DCVC Bio. more ➔
PCR-test reveals risk of genotoxity of gen...German researchers have presented a new method to assess on-target and off-target effects of CRISPR-Cas nucleases or TALENs. more ➔
